Page last updated: 2024-12-06
aldrin-transdiol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
aldrin-transdiol: dieldrin metabolite suggested as active neurotoxic form; RN refers to (1 alpha,2 alpha,3 beta,4 alpha,4a beta,5 alpha,8 alpha,8a beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 121492700 |
MeSH ID | M0049034 |
Synonyms (16)
Synonym |
---|
5,6,7,8,9,9-hexachloro-1,2,3,4,4a,5,8,8a-octahydro-1,4:5,8-dimethanonaphthalene-2,3-diol |
trans-6,7-dihydroxydihydroaldrin |
wl 40549 |
trans-aldrindiol |
1,4:5,8-dimethanonaphthalene-2,3-diol, 5,6,7,8,9,9-hexachloro-1,2,3,4,4a,5,8,8a-octahydro-, stereoisomer |
aldrin-transdiol |
h9afn5yd9r , |
3106-29-4 |
unii-h9afn5yd9r |
aldrindiol, trans- |
wl-40549 |
1,4:5,8-dimethanonaphthalene-2,3-diol, 5,6,7,8,9,9-hexachloro-1,2,3,4,4a,5,8,8a-octahydro-, (1r,2s,3s,4s,4ar,5r,8s,8as)-rel- |
(1s,2s,3r,4s,5s,6s,7r,8r)-1,8,9,10,11,11-hexachlorotetracyclo[6.2.1.13,6.02,7]dodec-9-ene-4,5-diol |
Q27279794 |
DTXSID40953167 |
AKOS040750312 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" The toxicology of dihydrodiol is more complex than what can be deduced solely on the basis of diminished bioavailability of the epoxide precursor, and the increased hydrophilicity associated with the dihydrodiol moiety." | ( Toxicological significance of dihydrodiol metabolites. Hsia, MT, 1982) | 0.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |